It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
How cancer cells cope with high levels of replication stress during rapid proliferation is currently unclear. Here, we show that macrophage migration inhibitory factor (MIF) is a 3’ flap nuclease that translocates to the nucleus in S phase. Poly(ADP-ribose) polymerase 1 co-localizes with MIF to the DNA replication fork, where MIF nuclease activity is required to resolve replication stress and facilitates tumor growth. MIF loss in cancer cells leads to mutation frequency increases, cell cycle delays and DNA synthesis and cell growth inhibition, which can be rescued by restoring MIF, but not nuclease-deficient MIF mutant. MIF is significantly upregulated in breast tumors and correlates with poor overall survival in patients. We propose that MIF is a unique 3’ nuclease, excises flaps at the immediate 3’ end during DNA synthesis and favors cancer cells evading replication stress-induced threat for their growth.
Replication stress is associated with cancer formation and progression. Here the authors reveal that the macrophage migration inhibitory factor (MIF) functions as 3’ flap nuclease involved in resolving replication stress affecting overall tumor progression.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details





1 UT Southwestern Medical Center, Department of Pathology, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
2 UT Southwestern Medical Center, Department of Radiation Oncology, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
3 UT Southwestern Medical Center, Department of Internal Medicine, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
4 UT Southwestern Medical Center, Department of Pathology, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); UT Southwestern Medical Center, Department of Pharmacology, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
5 UT Southwestern Medical Center, Department of Pathology, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); UT Southwestern Medical Center, Department of Neurology, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)